AstraZeneca PLC (AZNCF)
| Market Cap | 251.76B |
| Revenue (ttm) | 58.13B |
| Net Income (ttm) | 9.40B |
| Shares Out | n/a |
| EPS (ttm) | 6.02 |
| PE Ratio | 26.79 |
| Forward PE | 17.09 |
| Dividend | 3.13 (1.89%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 435 |
| Average Volume | 1,843 |
| Open | 165.25 |
| Previous Close | 156.50 |
| Day's Range | 165.25 - 169.00 |
| 52-Week Range | 120.64 - 175.00 |
| Beta | 0.17 |
| RSI | 52.14 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
UK will only be able to afford generic drugs if NHS fails to pay more, says AstraZeneca boss
Pascal Soriot says cost-effectiveness thresholds for new medicines have not changed for two decades Business live – latest updates The boss of AstraZeneca has said that unless the UK ramps up spending...
AstraZeneca's 9M and Q3 2025 Financial Results
CAMBRIDGE, England--(BUSINESS WIRE)--Q3 2025 Results Release.
AstraZeneca (AZN) Reports Q3 Revenue as Company Eyes Growth with Phase III Trials
AstraZeneca (AZN) Reports Q3 Revenue as Company Eyes Growth with Phase III Trials
AstraZeneca Stuns Wall Street With Surprise Profit Surge
AstraZeneca Stuns Wall Street With Surprise Profit Surge
AstraZeneca (AZN) Surpasses Q3 Expectations with Strong Oncology Sales
AstraZeneca (AZN) Surpasses Q3 Expectations with Strong Oncology Sales
AstraZeneca (AZN) Exceeds Expectations and Confirms 2025 Outlook
AstraZeneca (AZN) Exceeds Expectations and Confirms 2025 Outlook
AstraZeneca beats Q3 estimates on oncology strength
AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO
AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.
AstraZeneca (AZN) Surpasses Q3 Earnings and Revenue Expectations
AstraZeneca (AZN) Surpasses Q3 Earnings and Revenue Expectations
AstraZeneca’s strong U.S. ties reflect Trump’s policy of equalization, says CEO
AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.
Earnings Snapshot: AstraZeneca tops Q3 estimates; reaffirms FY 25 outlook
AstraZeneca beats top-line and bottom-line estimates; reaffirms FY25 outlook
AstraZeneca Q3 Results Climb, Top Estimate; Backs FY25 Outlook
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) reported Thursday significantly higher profit in its third quarter with good growth in revenues. Core earnings and top line beat market est...
AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal
The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to $15.19 billion from $13.57 billion.
AstraZeneca beats third-quarter revenue and profit expectations
AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London's most valuable listed company to retain its fu...
Pre-Market Earnings Report for November 6, 2025 : AZN, COP, PH, CNQ, VST, WBD, APD, TRP, BDX, DDOG, ROK, NRG
The following companies are expected to report earnings prior to market open on 11/06/2025. Visit our Earnings Calendar for a full list of expected earnings releases.Astrazeneca PLC (AZN)is reporting ...
AstraZeneca (AZN) Prepares for Q3 Earnings Announcement
AstraZeneca (AZN) Prepares for Q3 Earnings Announcement
AstraZeneca Q3 2025 Earnings Preview
Time for Reeves to recognise reality: AstraZeneca has killed stamp duty on shares | Nils Pratley
Shareholder-backed plans to upgrade US listing have exposed multiple flaws in tax that should be abolished or at least cut It was one of those votes where the majority was always going to be huge. Ast...
AstraZeneca (AZN) Shareholders Approve New Articles for Equity Listing Structure
AstraZeneca (AZN) Shareholders Approve New Articles for Equity Listing Structure
AstraZeneca wins shareholder backing for NYSE listing in US pivot
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025
LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first...
Megacap earnings to dominate next week as government shutdown continues. 11/3/25
The ongoing government shutdown is set to become the second-longest in U.S. history, creating a major hurdle for equities and commodities despite a trade truce with China and a recent Fed rate cut. 10...
AstraZeneca (AZN) Begins Phase 3 Trial for Enhertu in Lung Cancer Treatment
AstraZeneca (AZN) Begins Phase 3 Trial for Enhertu in Lung Cancer Treatment